180 related articles for article (PubMed ID: 9548450)
1. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
[TBL] [Abstract][Full Text] [Related]
2. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
3. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
7. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.
Jankevicius F; Goebell P; Kushima M; Schulz WA; Ackermann R; Schmitz-Dräger BJ
Urol Int; 2002; 69(3):174-80. PubMed ID: 12372883
[TBL] [Abstract][Full Text] [Related]
8. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
11. Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract.
Shinohara N; Nonomura K; Takakura F; Hamada M; Grossman HB; Koyanagi T
Eur Urol; 1994; 26(4):327-33. PubMed ID: 7713132
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
[TBL] [Abstract][Full Text] [Related]
13. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
14. Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review.
Cordier J; Sonpavde G; Stief CG; Tilki D
World J Urol; 2013 Feb; 31(1):77-82. PubMed ID: 23053212
[TBL] [Abstract][Full Text] [Related]
15. [Molecular biological testing for diagnosis and treatment of urothelial cancer].
Kakehi Y
Hinyokika Kiyo; 1999 Aug; 45(8):583-8. PubMed ID: 10500967
[TBL] [Abstract][Full Text] [Related]
16. [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].
Fontana LO; García García F; Arcas Martínez Salas I; García Ligero J; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Canteras Jordana M
Arch Esp Urol; 2002 Sep; 55(7):792-6. PubMed ID: 12380307
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
18. Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin.
Flamm M; Brodowicz T; Haitel A; Susani M; Tomek S; Köstler W; Pycha A; Kratzik C; Marberger M; Zielinski CC
Anticancer Res; 2002; 22(2B):1295-300. PubMed ID: 12168940
[TBL] [Abstract][Full Text] [Related]
19. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
Sarkis AS; Bajorin DF; Reuter VE; Herr HW; Netto G; Zhang ZF; Schultz PK; Cordon-Cardo C; Scher HI
J Clin Oncol; 1995 Jun; 13(6):1384-90. PubMed ID: 7751883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
